Vaxart, Inc.
VXRT · OTCMCIK 72444fmd_10AKX9R1E8W8R585K4ZPTKCZHRManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Dec 28, 2008 to Sep 30, 2026, 69 periods
| Line item | FY2017 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 6 | 4 | 10 | 4 | 1 | 0 | 7 | 29 | 237 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | (0) | – | – | – | – | – | – | – |
| Research and development | – | 12 | 17 | 15 | 20 | 49 | 81 | 68 | 74 | 202 |
| Total operating expenses | – | – | 26 | 26 | 34 | 74 | 115 | 91 | 95 | 219 |
| Operating income | – | (10) | (22) | (16) | (30) | (73) | (115) | (83) | (66) | 18 |
| Interest expense | – | 3 | 1 | 0 | 0 | 0 | – | – | – | – |
| Interest and investment income | – | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | 0 | 4 | (2) | – | – | – | (0) | 0 | (0) |
| Income before taxes | (29) | – | (18) | (18) | (32) | (70) | (108) | (82) | (67) | 17 |
| Income tax expense | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (29) | – | (18) | (19) | (32) | (70) | (108) | (82) | (67) | 16 |
| Net income | – | (10) | (18) | (19) | (32) | (70) | (108) | (82) | (67) | 16 |
| Net income to common shareholders | – | (12) | (18) | (19) | (32) | – | – | – | – | – |